PLAINSBORO, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) recently organized a hands-on regenerative wound management workshop at the Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas, Nevada. The workshop, led by renowned wound care experts John Lantis, MD, and Paul Kim, DPM, focused on best practices for outpatient chronic wound management, including the use of Integra® dermal regenerative technologies in the chronic wound environment. A unique combination of a hands-on skills lab and lecture attracted surgeons, physicians, and mid-level healthcare providers.
“Many chronic wounds need more than just re-epithelialization strategies,” said Dr. Kim, a leading foot and ankle surgeon at Georgetown University Hospital. “This workshop highlighted the importance of good wound care practices, such as good wound bed preparation, to maximize the benefits of dermal regeneration technologies.”
Additionally, nine posters were presented by surgeons and wound care specialists on their latest clinical experiences, using Integra products for wound management. These posters featured the use of PriMatrix for the management of full-thickness chronic wounds and complex pressure ulcer reconstructions as well as a sub-analysis of the Omnigraft® FOot Ulcer New DErmal Replacement (FOUNDER) study.
John Lantis, MD, a leading vascular surgeon at Mount Sinai St Luke’s and Mount Sinai West Hospitals, independently presented his work on using PriMatrix for the management of complex wounds with exposed subcutaneous structures.
“Providing optimal wound care is essential in helping our patients enhance their quality of life,” said Dr. Lantis. “PriMatrix has become an important part of my limb preservation practice and helps me treat patients with very challenging wounds.”
The SAWC serves as a forum to connect physicians, nurses, clinical researchers and scientists with leading experts in wound care, improving patient outcomes through collaboration and education. More than 1,300 healthcare professionals attended the Fall meeting.
About the FOUNDER Study
The FOot Ulcer New DErmal Replacement (FOUNDER) study was a multi-center, randomized, controlled, parallel group clinical trial conducted under an Investigational Device Exemption (IDE). The pivotal clinical trial enrolled 307 patients at 32 sites, and patients were followed for up to 29 weeks. The primary endpoint of the study was the incidence of complete wound closure at 16 weeks. The secondary outcome measures included time to complete wound closure, incidence of recurrence, and quality of life. The median number of applications per patient, including the initial application, for the IDRT group was one. The results from the FOUNDER study were printed in the November/December issue of Wound Repair and Regeneration in the publication, “A Clinical Trial of Integra® Template for Diabetic Foot Ulcer Treatment.”
About Omnigraft® Dermal Regeneration Matrix
Omnigraft® Dermal Regeneration Matrix is the only FDA approved product that regenerates dermal tissue. It is an advanced bi-layer dermal regeneration matrix indicated for use in the treatment of partial and full-thickness neuropathic diabetic foot ulcers (DFUs) that are greater than six weeks in duration, with no capsule, tendon or bone exposed, when used in conjunction with standard diabetic ulcer care. Based on the FOUNDER study, Omnigraft increases the incidence of wound closure by 59%, increases the average rate of wound size closure by 50%, and reduces the median time to wound closure by five weeks, compared to conventional therapy. Additionally, Omnigraft healed patients with fewer applications, with 92% of those who healed requiring two applications or fewer.
About PriMatrix® Dermal Repair Scaffold
PriMatrix® Dermal Repair Scaffold is a unique dermal repair scaffold made with proprietary processing technology that purifies fetal bovine dermis and preserves the beneficial properties of the natural fetal dermal collagen fibers. PriMatrix is indicated for the management of wounds that include: partial and full thickness wounds; pressure, diabetic, and venous ulcers; second-degree burns; surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence); trauma wounds (abrasions, lacerations and skin tears); tunneled/undermined wounds; and draining wounds.
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Investors Angela Steinway 609-936-2268 firstname.lastname@example.org Michael Beaulieu 609-750-2827 email@example.com Media Laurene Isip 609-750-7984 firstname.lastname@example.org